Human Rejuvenation Test Begins—In an Eye

A Boston biotech company just put a partial anti-aging therapy into a human eye for the first time in history.

Quick Take

Life Biosciences dosed its first patient in a Phase 1 trial testing ER-100, a therapy built on partial epigenetic reprogramming.
The Food and Drug Administration (FDA) cleared the trial in January 2026 to test safety in glaucoma and a form of optic nerve damage called NAION.
Harvard scientist David Sinclair co-founded the company and says the therapy uses a trimmed-down set of genes tied to cell rejuvenation.
The trial is designed to check safety first, but it will also track whether patients’ vision actually improves.
The company raised 80 million dollars to fund this work, adding financial weight behind the launch.

What Life Biosciences Actually Announced

Life Biosciences said the FDA cleared its application to test ER-100 in humans back in January 2026. By June, the company announced it had dosed its first patient in that same Phase 1 trial. The study targets two eye conditions: open-angle glaucoma and a stroke-like optic nerve injury known as NAION. Both diseases can steal a person’s sight and currently have limited treatment options.

The company plans to enroll between 12 and 18 people in this early study. Doctors will watch for safety problems, immune reactions, and any signs the treatment is working. Because this trial involves actual patients rather than healthy volunteers, Life Biosciences says it will also track real changes in vision, not just whether the drug is safe.

The Science Behind The Needle

ER-100 grew out of years of mouse research led by Sinclair’s lab. Scientists used a partial version of the famous Yamanaka reprogramming genes, cutting the four down to three. In mice, this approach restored damaged DNA patterns in eye cells and reversed vision loss caused by both aging and glaucoma. Sinclair has called the human trial an extension of that same idea.

The theory rests on a simple but bold claim. Aging cells lose track of their original instructions, like a book with smudged pages. Partial reprogramming, in theory, cleans the smudges without erasing what type of cell it is. Full reprogramming can turn a cell into a blank slate, which risks cancer. Sinclair’s team says the partial version avoids that danger while still restoring youthful function.

Why This Trial Carries Extra Weight

This is the first time this kind of therapy has been tested in a person anywhere in the world. That milestone matters beyond eye disease. If partial reprogramming proves safe in the eye, it could open the door to testing the same idea in other organs affected by aging. The eye works well as a starting point because doctors can watch it closely and measure results directly.

Life Biosciences recently closed an 80 million dollar funding round to push this work forward. That kind of investment signals real confidence from people willing to bet money on the science. It also means the company has strong reason to publicize good news quickly, which readers should keep in mind as more updates arrive in the coming months.

What Comes Next For Patients And Watchers

This trial is still in its earliest phase, and Phase 1 studies exist mainly to check safety, not to prove a cure works. No results on vision improvement have been released yet. Anyone hoping for headlines about restored eyesight will need to wait for further data as more patients get dosed and doctors track outcomes over the coming months.

Gene and cell therapies for eye disease have a track record worth noting. Earlier trials for inherited blindness showed lasting benefits tracked over several years, proving this general approach can work over time. That history gives some reason for cautious optimism here, even though ER-100 works through a different mechanism and still has a long road of testing ahead.

For now, the facts are straightforward. A real trial is underway, a real patient has been dosed, and real regulators signed off on it. What happens next depends on data nobody has seen yet. Readers who care about aging science, blindness treatment, or simply where medicine is headed have good reason to keep watching this one closely.